Selumetinib in thyroid cancer. New trial conducted by AZN.
Official Title: A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer
This trial should be pivotal although it is Phase 2. Study starts in June and if the results are positive, AZN will file NDA.